S&P Futures
4,245.50-1.00(-0.02%)Dow Futures
34,242.00-46.00(-0.13%)Nasdaq Futures
14,046.75+16.50(+0.12%)
Virpax Pharmaceuticals, Inc. (VRPX)
Chart Events
Performance Outlook
| Previous Close | 4.2200 |
| Open | 4.1900 |
| Bid | 3.9100 x 1400 |
| Ask | 0.0000 x 1100 |
| Day's Range | 3.9590 - 4.2800 |
| 52 Week Range | 3.7900 - 8.2400 |
| Volume | 339,654 |
| Avg. Volume | 251,763 |
| Market Cap | 20.028M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET. Anthony Mack, Chairman and CEO of Virpax, will be giving the presentation.
- Business Wire
Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments.
- Business Wire
Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets.
